Swiss Health Valley medtech Aspivix, based at Biopôle, has successfully closed its second crowdfunding campaign on Capital Cell, raising €836,285 against an initial target of €675,545, a 123.8% oversubscription that confirms investors’ continued appetite for the company’s story.

Aspivix develops carevix®, a CE-marked, FDA-approved cervical stabilizer designed to replace traditional Pozzi forceps in gynecological procedures such as IUD insertion. Clinical trials have shown significant reductions in pain, bleeding, and cervical trauma compared to conventional instruments, and the device is now marketed in 19 countries, generating commercial revenue.

This latest success builds directly on the company’s first public fundraising effort, which ultimately raised over €1.9 million from more than 300 investors.

The proceeds will fuel Aspivix’s commercial expansion across the US and Europe, strengthen its market traction, and support development of carevix® EVO, the company’s next-generation platform.

“A heartfelt thank you to everyone who invested, shared our ambition and gave us another powerful push forward. Your support helps us accelerate the commercialization of carevix® and continue challenging the status quo in women’s healthcare. Our journey does not stop here: we will now continue our fundraising with institutional investors.,” said CEO Matthieu Horras.

Once again, Aspivix is proving that Swiss Health Valley innovation in women’s health doesn’t just attract clinicians and hospitals — it attracts capital, too.

Source: Capital Cell | © Aspivix’s Team

The post A New Crowdfunding Success for Aspivix appeared first on BioAlps.

The 3rd International Annual Conference on Artificial Intelligence in Health (aiHealth2026) which will take place 10-11 November 2026 at the University of Applied Sciences and Arts Northwestern Switzerland FHNW in Muttenz

Over one and a half days we will embark on an exploration of today’s healthcare landscape, explore the transformative power of artificial intelligence (AI) in revolutionizing the way we perform individualized diagnostics, discover therapeutics and map the population health-disease continuum through future citizen twins towards one health.

aiHealth2026 offers three sessions focused on the applications of artificial intelligence in health:

• AI for Diagnostics
• AI for Therapeutics
• AI in Citizen Health

The Conference will feature insightful presentations to elucidate the latest findings from artificial intelligence applications in both traditional and digital medicine, investigate common challenges and promises and explore their potential future merger into digital twins for health through engaging discussions. Reflecting the spirit of translational medicine and digital transformation, agile interactive panel discussions will showcase on-screen emerging applications of AI addressing diagnostics, therapeutics and citizen health.

10-11 November 2026 | University of Applied Sciences and Arts Northwestern Switzerland FHNW in Muttenz | More Information

The post Annual Conference on Artificial Intelligence in Health (aiHealth2026) appeared first on BioAlps.

The Innover Ensemble event is taking place on 22 September 2026 at the University Medical Center in Geneva

Researchers at UNIGE, start-ups and businesses in Geneva – do you have an innovative project? The University of Geneva’s Research Support Service (SSR) and Euresearch, with the support of the Republic and Canton of Geneva, invite you to an information and networking event dedicated to the funding opportunities available to you. On the programme: a presentation of the Innosuisse and Eureka/Eurostars schemes, real-life testimonials from beneficiary companies, Q&A sessions and a networking opportunity with key players in Geneva’s innovation ecosystem.

Programme

• 4.15 pm – 4.30 pm: Registration
• 4.30 pm – 4.35 pm: Welcome address, Sébastien Castelltort, Vice-Rector for Research (UNIGE)
• 4.35 pm – 4.45 pm: Presentation of the Research Support Service (SSR) and Euresearch
• 4.45 pm–5.00 pm: Innosuisse innovation programmes, Jérome Michaud, Innosuisse mentor
• 5.00 pm–5.15 pm: Case study: FluoSphera, a UNIGE spin-off
• 5.15 pm–5.25 pm: Q&A session on Innosuisse
• 5.25–5.40 pm: Eureka and Eurostars programmes, Janique Siffert, Swiss Eurostars Project Coordinator
• 5.40–5.50 pm: OrbiWise case study
• 5.50–6.00 pm: Q&A on Eureka and Eurostars

22 September 2026, from 4.30 PM | University Medical Centre (CMU), Faculty of Medicine, University of Geneva, Alex-F. Müller Lecture Theatre (formerly A250), Rue Michel-Servet 1, 1206 Geneva | More Information

The post Innover Ensemble appeared first on BioAlps.

The Next-gen organ-on-chips & organoids workshop, organised by CSEM, is taking place on 20-21 January 2027 in Bern

This dynamic two-day event at the forefront of bioconvergence. This is your chance to connect with key decision-makers from the pharma and biotech industries, clinicians, organ-on-chips suppliers, regulatory experts, and leading research organizations. Our workshop features inspiring keynote presentations from top-tier speakers and offers a unique platform to:

• Propel the translation of advanced in-vitro models into clinical and drug development applications
• Innovate with groundbreaking technologies to create cutting-edge products and services
• Navigate and overcome the challenges of adopting new methods and technologies in a regulated environment

Don’t miss out on this unparalleled opportunity to engage, network, and showcase your organization to a vibrant community of industry leaders.

20-21 January 2027 |Bernexpo, Mingerstrasse 6, 3014 Bern |  Price: CHF 300.- for both days (it will not be possible to register for 1 day only) | Information and Registration

The post Next Gen Organ-on-Chip & Organoids Workshop appeared first on BioAlps.

This seminar, organised by Databio, is taking place on 29 October 2026 at EPFL Innovation Park.

This one-day immersive and intensive practical workshop is exploring the ethical and legal use of general-purpose large language models (gLLM, eg. Chat-GPT, Claude, Gemini, Copilot) in scientific research. Participants leave with very applied recipes to build AI governance applied to gLLM in the lab. The seminar is particularly tailored to life sciences scientists, from industry and academia.

Content overview:
– Introduction to ethics and law in the gLLM world.
– Transparency and reliability in non-clinical research.
– The clinical issues of privacy, consent and bias.
– gLLM in peer review: the complex equation.
– Comparison of chatbots.
– Interactive workshop

29 October 2026 |EPFL Innovation Park | Registration (Academia: CHF 200 | Industry: CHF 300)

The post Trustworthy by design: building robust AI guidelines for ethical research appeared first on BioAlps.

The Swiss HLG Afterwork, Carve Outs in Pharma and Beyond, is taking place on 1 October 2026 at Campus Biotech In Geneva

Be part of an insightful evening co‑hosted by Swiss HLG and Gyrus Capital to explore one of the most powerful value creation strategies in healthcare and life sciences: carve-outs.
By separating non-core assets or businesses into independent companies, carve-outs can unlock hidden value, sharpen strategic focus, and create platforms for sustainable growth.

 Keynote Speaker:
Etienne Jornod: Executive Chairman of OM Pharma, Former Executive Chairman Galenica and Vifor, Former Chairman NZZ and Director Alliance Boots (KKR), will share insights from the successful spin‑out of OM Pharma from Vifor and the lessons learned from this transformative transaction.

 Market and Strategic Insights:
Elsa Torchet: Director, Life Sciences, Strategy and Business Design, Deloitte
Igor Heinzer: Partner – Head of Valuation and Modelling, Deloitte

 Investor and Operational Insights:
Anna Mattsson: Senior Partner at McKinsey & Company
Becki Morison: CEO, Essential Pharma
Robert Watson: Co-founder, Gyrus Capital

1 October 2026 | Campus Biotech, Geneva | Register

The post Swiss HLG Afterwork: Carve Outs in Pharma and Beyond appeared first on BioAlps.

Swiss Nordic Bio conference is taking place in Zurich on 1 October 2026. 

Swiss Nordic Bio is the number one platform connecting healthcare innovators with investors and industry. Together with Nordic, Swiss, Austrian and German partner organizations, and leading European investors and pharmaceutical companies. The purpose is to foster investment opportunities, licensing, and R&D collaborations.

• Gain access to leading investors from Europe such as HealthCap, Bank Vontobel, BlackRock, HSBC, and many more…
• Meet decision-makers from global leaders like Johnson & Johnson, Roche, Novartis Venture Fund, Boehringer Ingelheim, Debiopharm, and more…
• Discuss funding, licensing, and innovation collaboration opportunities during pre-booked one-to-one meetings.
• Discover cutting-edge Life Science and MedTech SMEs.
• If you secured your first large investment, meet new investors.

1 October 2026 |Radisson Blu Hotel, Zürich Airport | Register here | Swiss SMEs have 50% of the participation fee covered through Innosuisse using promotion code: CH1_SNB_2026 or SU1_SNB_2026

The post Swiss Nordic Bio appeared first on BioAlps.

Sixteen startups from the Swiss Health Valley ecosystem are landing in the Top 100 — They have been recognized in Venturelab’s Top 100 Swiss Startup Ranking, the country’s benchmark list of its most promising young companies. Corinthis (VD), DeepJudge (ZH) and Pave Space (VD) are on the podium.

For 16 years, a jury of 100 leading investors and startup experts has selected the 100 most promising Swiss startups each year. The ranking has become a trusted reference point for founders, investors, and the wider Swiss startup ecosystem — and this year, health and life sciences ventures from Western Switzerland make up a striking share of the list. Here’s the full Health Valley lineup:

#5 — Seprify (Biotech, FR)
Develops cellulose-based industrial ingredients — inspired by the light-scattering structure of the Cyphochilus beetle — to replace titanium dioxide in everyday products.

#11 — Clee Medical (Medtech, GE)
A Wyss Center spin-off bringing real-time AI-powered imaging to brain surgery, giving surgeons clearer visibility during operations.

#28 — Herosupport SA (Medtech, GE)
Makes custom, 3D-printed patient-positioning shells for radiotherapy, improving precision, safety, and comfort — starting with breast cancer treatment.

#21 — Tune Insight (Healthcare, Security, VD)
Builds privacy-preserving data collaboration technology using homomorphic encryption, letting hospitals and organizations jointly analyze sensitive data without ever exposing it.

#33 — Bewelab (Digital Health, VD)
A gamified mobile app that uses neuroplasticity-based brain training to help people reduce unhealthy food cravings and improve metabolic health.

#33 — Ovomind (ICT, GE)
Converts biosignals into real-time emotional data, powering emotion-driven AI for gaming and human-machine interaction.

#34 — planetary (Foodtech, GE)
Runs a fermentation platform that produces sustainable, animal-free proteins at scale for the food industry.

#35 — Dexterous Endoscopes (BIND 2026 Winner) (Medtech, VD)
Developing next-generation flexible endoscopic devices for safer, more precise minimally invasive procedures; named Top100 Newcomer of the Year 2026.

#46 — Immitra Bio GmbH (Biotech)
Developing gene therapies built on hematopoietic stem cells.

#48 — Perivision SA (Medtech, Digital Health, VD)
An AI- and VR-based eye-testing platform that makes assessing visual function faster and more accessible.

#54 — Bioscibex SA (Biotools, VS)
Manufactures single-use bioreactor systems that automate cell culture from 30 mL to 30 L, from early research through to manufacturing scale.

#73 — Actival SA (Medtech, VD)
Designs active dental aligners with built-in hygiene technology for orthodontic treatment.

#87 — Calico Biosystems SA (Biotool, VD)
A platform that predicts anti-cancer drug efficacy early, helping speed up oncology drug development.

#94 — Isospec Analytics (Biotool, VD)
A platform for rapidly identifying unknown molecules at scale, accelerating molecular discovery.

#95 — Adaptyv Biosystems (Biotech, Engineering)
An automated, AI-powered protein engineering platform — described as “the automated lab for agentic biology.”

#100 — Xemperia (Biotech, FR)
Developing blood-test-based technology aimed at transforming breast cancer detection.

To every founder and team on this list: rankings are nice, but we know the hard work that goes on behind them. Congratulation on this amazing journey!

Discover the full Top 100 ranking here

The post 16 Swiss Health Valley Startups Named Among Switzerland’s Top 100 appeared first on BioAlps.

The Foundation for Technological Innovation (FIT) announces its support for two new Vaud-based start-ups. Dexterous Endoscopes has secured a CHF 100,000 Tech Seed loan for its endoscope, which can switch from a flexible to a rigid state during the same procedure. Precisia Care has also received a CHF 100,000 Tech Seed loan for its hospital data analysis platform, designed to anticipate patient needs and staff workload.

Dexterous Endoscopes: an endoscope that changes rigidity mid-procedure

In minimally invasive surgery, doctors insert a camera and instruments through small incisions. Today, they must choose between two types of endoscope: rigid models, which are precise but unable to reach hard-to-access areas, and flexible models, which can navigate anywhere but bend as soon as force is required. Surgeons are consequently forced to switch instruments mid-operation, or even abandon the minimally invasive approach altogether.

Dexterous Endoscopes is developing a unique endoscope that combines both properties. The device moves in flexible mode to reach the target area, then stiffens at the push of a button to allow precise intervention. Dexterous Endoscope also got this year the BIND – BioInnovation Day Best Startup Award 2026.

The start-up has raised over one million francs in funding and completed seven rounds of preclinical trials on a working prototype. With the CHF 100,000 Tech Seed loan awarded by FIT, Dexterous Endoscopes will be able to continue its preclinical trials and prepare the regulatory and industrialisation stages for its device.

Precisia Care: anticipating patient needs from hospital data

In hospitals, a significant amount of patient information remains difficult to use: it is scattered across multiple systems and recorded as free-text notes by healthcare staff. Teams lack the tools to anticipate how a patient’s condition will evolve and to allocate workload accordingly.

Designed by specialists from the hospital and healthcare sector, Precisia Care’s platform analyses this data to generate predictive insights: workload assessment for care teams, patient safety alerts, and support for care organisation. It is already deployed in leading Swiss hospitals.

The CHF 100,000 Tech Seed loan awarded by FIT completes the budget needed to bring this project to completion and validate the ongoing pilot deployments at the Ensemble Hospitalier de la Côte (EHC) and the Réseau Hospitalier Neuchâtelois (RHNe).

Source: Press Release | © Dexterous Endoscope and Precisia Care

The post Dexterous Endoscopes and Precisia Care receive support from FIT appeared first on BioAlps.

The 4th edition of the Swiss RNA is taking place on 28 January 2027 at the University of Bern

The Swiss RNA Therapeutics Summit brings together stakeholders from academia, biotechnology, the pharmaceutical industry, manufacturing, government and regulatory bodies to foster collaboration in the rapidly advancing field of RNA therapeutics. The Swiss RNA Therapeutics Summit is an initiative of the Swiss Initiative for RNA & Disease (SIRD). 

28 January 2027 | University of Bern | Information and Registration

The post Swiss RNA Summit appeared first on BioAlps.